PHASE-II STUDY OF BETASERON (BETA-SER17-INTERFERON) AS TREATMENT OF ADVANCED MALIGNANT-MELANOMA
- 1 August 1987
- journal article
- research article
- Vol. 6 (4), 375-378
Abstract
Betaseron (.beta.ser17-interferon) was administered to 19 patients (17 evaluable) with advanced melanoma by two schedules. Patients received either 30 .times. 106 units (mU) by intravenous bolus 5 days a week for 2 weeks followed by 2 weeks rest, or 30mU daily for 5 days in week 1, 60 mU daily for 5 days in week 2, then twice-weekly doses escalating from 90 to 270 mU. Toxicity commonly included malaise, fatigue, fever, and weight loss. Mild hematologic, gastrointestinal, and hepatic toxicity were also seen, as well as an episode of atrial fibrillation in a patient with mitral valvular disease. No responses to therapy occurred.This publication has 7 references indexed in Scilit:
- PHASE-I STUDY OF RECOMBINANT BETA-SER 17 INTERFERON IN THE TREATMENT OF CANCER1986
- PHASE-I EVALUATION OF A SYNTHETIC MUTANT OF BETA-INTERFERON1985
- Site-specific mutagenesis of the human fibroblast interferon gene.Proceedings of the National Academy of Sciences, 1984
- Toxicity and response criteria of the Eastern Cooperative Oncology GroupAmerican Journal of Clinical Oncology, 1982
- ANTI-TUMOR EFFECT OF HUMAN FIBROBLAST INTERFERON ON THE GROWTH OF HUMAN-MELANOMA CELLS IMPLANTED IN NUDE-MICE1982
- COMPARATIVE ANTIPROLIFERATIVE ACTIVITY INVITRO OF NATURAL INTERFERON-ALPHA AND INTERFERON-BETA FOR DIPLOID AND TRANSFORMED HUMAN-CELLS1982
- Human leukocyte and fibroblast interferons are structurally relatedNature, 1980